GoldenGolden
Advanced Search
BioNTech

BioNTech

BioNTech is a German company that develops immunotherapies for the treatment of cancer and other diseases.

Contents
Approach
PipelineCOVID-19
Timeline
Funding rounds
Products
Acquisitions
People
Further reading
Documentaries, videos and podcasts
Companies
News
References

Primarily focused on developing individualized cancer therapy, BioNTech is a biotechnology company located in Mainz, Germany.

Approach

Their method revolves around several platforms in medicine; mRNA Therapeutics, engineered cell therapies, antibodies, and small molecule immunomodulators. Coupled with their approach to patient specific needs, they have seen success in providing unique treatments.

  1. Sequencing patient's tumor
  2. Mapping of mutations
  3. Bioinformatic algorithms
  4. Selection of neoepitopes
Pipeline
COVID-19

BNT162 is BioNTech’s mRNA vaccine program aimed at preventing COVID-19 infection. It is the first product candidate from Project Lightspeed and leverages BioNTech’s proprietary mRNA platforms for infectious diseases, its fully-owned GMP manufacturing infrastructure for mRNA vaccine production, and its global clinical development capabilities, drawing on BioNTech’s network of global collaborators. BioNTech is partnered with Pfizer for co-development and distribution of BNT162 and with Fosun Pharma on the vaccine development in China.

Timeline

November 25, 2020
BioNTech and Shanghai Fosun Pharmaceutical says they will launch a Phase II clinical trial of BioNTech's experimental COVID-19 vaccine in China.
November 12, 2020
Commission approves contract with BioNTech-Pfizer alliance to ensure access to a potential vaccine

The European Commission approved a fourth contract with pharmaceutical companies BioNTech and Pfizer, which provides for the initial purchase of 200 million doses on behalf of all EU Member States, plus an option to request up to a further 100 million doses, to be supplied once a vaccine has proven to be safe and effective against COVID-19. Member States can decide to donate the vaccine to lower and middle-income countries or to re-direct it to other European countries.

September 15, 2020
BioNTech raises a $455,600,000 grant.
June 29, 2020
BioNTech raises a $250,000,000 venture round from Temasek Holdings.
December 17, 2019
BioNTech raises a $60,747,000 venture round from European Investment Bank.
September 4, 2019
BioNTech raises a $55,000,000 grant from Bill & Melinda Gates Foundation.
July 9, 2019
BioNTech raises a $325,000,000 series B round from Fidelity Management & Research Company.
January 3, 2017
BioNTech raises a $270,000,000 series A round.
2009
BioNTech was founded by Christoph Huber and Ugur Sahin.

Funding rounds

Powered by Golden Research Engine

People

Name
Role
LinkedIn

Özlem Türeci

Chief Medical Officer

Ryan Richardson

Chief Strategy Officer

Sean Marett

Chief Business and Chief Commercial Officer

Sierk Poetting

Chief Financial Officer and Chief Operating Officer

Ugur Sahin

Chief Executive Officer

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

BioNTech Corporate Video

https://youtu.be/-7QOo7LXsp0

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioNTech founder Uğur Şahin and Mayfield's Ursheet Parikh are coming to Disrupt
Darrell Etherington
July 28, 2021
TechCrunch
It's hard to argue that any technology company has had a greater impact in the past decade than BioNTech, the mRNA-based therapeutics pioneer behind the world's most widely-used COVID-19 vaccine. Developed in record time in partnership with Pfizer, thanks to an existing partnership to work on immunization for the common flu, BioNTech's mRNA inoculation is [...]
BioNTech using COVID jab technology to develop effective malaria vaccine
Amar Mehta
July 26, 2021
Sky News
According to the World Health Organisation, there were 229 million cases of malaria globally in 2019, with 94% in Africa.
Vaccine maker BioNTech to use mRNA tech to target malaria
By FRANK JORDANS, Associated Press
July 26, 2021
Chron
BERLIN (AP) - Pharmaceutical company BioNTech said Monday that it wants to use the mRNA...
Vaccine maker BioNTech to use mRNA tech to target malaria
FRANK JORDANS Associated Press
July 26, 2021
ABC News
Pharmaceutical company BioNTech says it wants to use the mRNA technology behind its coronavirus vaccine to target malaria
Vaccine maker BioNTech to use mRNA tech to target malaria
July 26, 2021
AP NEWS
BERLIN (AP) -- Pharmaceutical company BioNTech said Monday that it wants to use the mRNA technology behind its coronavirus vaccine to target malaria.The Germany-based company, which developed the first widely approved coronavirus shot together with U.S.
African countries to receive six million Johnson and Johnson vaccines, the African Union says
July 24, 2021
News Track
Around six million doses of the single-shot Johnson & Johnson coronavirus vaccine will be delivered by the African Union to 27 African nations tha..|News Track
Taiwan tech giants Foxconn and TSMC to buy 10m Covid jabs
BBC News
July 12, 2021
BBC News
The government has come under intense pressure to speed up its vaccine programme.
Pfizer pushes for third shot as Delta drives global outbreaks
July 9, 2021
The Economic Times
Pfizer and BioNTech said they expected that a third dose will perform well against the strain, and that they would be seeking authorization in the United States, Europe and other regions in coming weeks.
COVID-19 News: New COVID-19 Vaccine Efficacy, MIS-C and More
BioSpace Editorial Staff
June 22, 2021
BioSpace
Please check out the biopharma industry's COVID-19 stories that are trending for June 22, 2021.
Western countries must share Covid vaccines - if only for the sake of their GDP
Phillip Inman
June 19, 2021
the Guardian
Optimistic forecasts about 'bouncing back' will only come true if new variants do not close borders and devastate trade again
Taiwan wants German vaccines. China may be standing in its way
June 16, 2021
The Economic Times
The impasse is exacerbating Taiwans vaccine shortage as the island confronts its first major outbreak of COVID-19 since the start of the pandemic.
CSafe Global biedt thermische bescherming voor COVID-19-vaccinzendingen vanuit BioNTech-vestiging
CSafe Global
June 16, 2021
www.prnewswire.com:443
/PRNewswire/ -- CSafe Global, innovatief marktleider op het gebied van actieve, passieve pakket- en cel- en gentemperatuurgecontroleerde containeroplossingen...
CSafe Global fornisce protezione termica per le spedizioni di vaccini per il COVID-19 dallo stabilimento di BioNTech
CSafe Global
June 15, 2021
www.prnewswire.com:443
/PRNewswire/ -- CSafe Global, leader nell'innovazione per il settore dei contenitori attivi e passivi, e a temperatura controllata destinati a soluzioni...
Inside story of the Pfizer BioNTech vaccine to be published by St. Martin's
June 9, 2021
WebWire
It was announced that the inside story of the first vaccine in the global fight against the Covid-19 pandemic will be told in The Vaccine: Inside the Race to Conquer the COVID-19 Pandemic. BioNTech founders and scientist couple Ugur Sahin and Özlem Türeci, who were the first to produce the vaccine, will tell their story to Joe Miller of the Financial Times. Publication of the book is planned for November 2, 2021. St. Martin's Publishing Group SVP/Editor-in-Chief George Witte acquired U.S....
BioNTech founders contributing to book on COVID-19 vaccine
By HILLEL ITALIE
June 8, 2021
AP NEWS
NEW YORK (AP) -- The husband and wife team who helped make the first COVID-19 vaccine are contributing to a book about their efforts. BioNTech founders Ugur Sahin and Özlem Türeci are collaborating with Joe Miller of the Financial Times on "The Vaccine," St.
BioSpace Movers & Shakers, May 21
Alex Keown
May 21, 2021
BioSpace
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.
Soaring stocks in pharma giants has minted these 9 new 'vaccine billionaires,' according to a report
Grace Dean
May 21, 2021
Business Insider
The wealth of the new billionaires, from Moderna, BioNTech, and others, could fully vaccinate 776 million in low-income countries, per the report.
Coronavirus Vaccines Have Spawned 9 New Billionaires: Campaign Group
May 20, 2021
NDTV.com
Profits from Covid-19 jabs have helped at least nine people become billionaires, a campaign group said Thursday, calling for an end to pharmaceutical corporations' "monopoly control" on vaccine technology.
Coronavirus Vaccines Have Spawned 9 New Billionaires: Campaign Group
May 20, 2021
NDTV.com
Profits from Covid-19 jabs have helped at least nine people become billionaires, a campaign group said Thursday, calling for an end to pharmaceutical corporations' "monopoly control" on vaccine technology.
Coronavirus Vaccines Have Spawned 9 New Billionaires: Campaign Group
May 20, 2021
NDTV.com
Profits from Covid-19 jabs have helped at least nine people become billionaires, a campaign group said Thursday, calling for an end to pharmaceutical corporations' "monopoly control" on vaccine technology.
SHOW MORE

References

biontech.de
Is a
Company

Company attributes

Industry
Location
Company status
Active
B2X
‌
B2C
CEO
Ugur Sahin
Founder
Crunchbase
crunchbase.com/organiz...ntech-ag
Legal name
BioNTech SE
Legal classification
Date incorporated
2009
Spun out from
Johannes Gutenberg University of Mainz
Number of Employees (ranges)
1,000 – 4,999
Full address
An der Goldgrube 12 55131 Mainz Germany
CIK number
1,776,985
Place of incorporation
Germany
Investors
Founded date
2008
Email address
info@biontech.de
Phone number
49 6131 9084-0
Fax number
49 6131 9084-390
Total funding amount (USD)
1,777,847,000
Latest funding round date
September 15, 2020
Competitors
Kernal Biologics
Business model
Commerce
Latest funding type
Series B round

Other attributes

Country
Germany

Categories

Related Topics

Contributors

Golden logo
Company
HomePress & MediaBlogCareers
We're hiring
Product
OverviewPricingEnterprise
Legal
Terms & ConditionsCommercial Terms & ConditionsPrivacy Policy
Help
Help centerAPI DocumentationContact Us
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.